Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-β binding to Vif

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Wang, Xiaodan ^a   Wang, Xiaoying ^a   Zhang, Haihong ^a   Lv, Mingyu ^a   Zuo, Tao ^a   Wu, Hui ^a   Wang, Jiawen ^a   Liu, Donglai ^a   Wang, Chu ^a   Zhang, Jingyao ^a   Li, Xu ^a   Wu, Jiaxin ^a   Yu, Bin ^a   Kong, Wei ^a   Yu, Xianghui ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

CBF ; Elongin BC complex; HIV 1; Protein binding; Ubiquitin protein ligases; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CORE BINDING FACTOR BETA; CULLIN; CULLIN 5; ELONGIN B; ELONGIN C; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; VIRION; VIRUS INFECTIVITY;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; CORE BINDING FACTOR BETA SUBUNIT; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; TRANSCRIPTION FACTORS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84883145366     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-94     Document Type: Article

References (78)

1. Malim MH, Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398. 10.1016/j.chom.2008.04.008, 18541215.
2. Lv W, Liu Z, Jin H, Yu X, Zhang L. Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org Biomol Chem 2007, 5:617-626. 10.1039/b612050d, 17285170.
3. Pomerantz RJ. The HIV-1 Vif protein: a paradigm for viral: cell interactions. Cell Mol Life Sci 2003, 60:2017-2019. 10.1007/s00018-003-3192-7, 14618252.
4. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 1992, 66:6489-6495. 240141, 1357189.
5. Romani B, Engelbrecht S, Glashoff RH. Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif. Arch Virol 2009, 154:1579-1588. 10.1007/s00705-009-0481-y, 19669862.
6. Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 2006, 80:10522-10533. 10.1128/JVI.01123-06, 1641744, 16920826.
7. Doehle BP, Schafer A, Cullen BR. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005, 339:281-288. 10.1016/j.virol.2005.06.005, 15993456.
8. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650. 10.1038/nature00939, 12167863.
9. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 2004, 78:6073-6076. 10.1128/JVI.78.11.6073-6076.2004, 415831, 15141007.
10. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 2004, 23:2451-2458. 10.1038/sj.emboj.7600246, 423288, 15152192.
11. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing?. Trends Biochem Sci 2007, 32:118-128. 10.1016/j.tibs.2007.01.004, 17303427.
12. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113:803-809. 10.1016/S0092-8674(03)00423-9, 12809610.
13. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060. 10.1126/science.1089591, 14564014.
14. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31. 10.1016/S0092-8674(03)00515-4, 12859895.
15. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 2005, 79:9579-9587. 10.1128/JVI.79.15.9579-9587.2005, 1181563, 16014920.
16. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003, 9:1404-1407. 10.1038/nm945, 14528300.
17. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003, 9:1398-1403. 10.1038/nm946, 14528301.
18. Wolfe LS, Stanley BJ, Liu C, Eliason WK, Xiong Y. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J Virol 2010, 84:7135-7139. 10.1128/JVI.00031-10, 2898223, 20463065.
19. Barraud P, Paillart JC, Marquet R, Tisne C. Advances in the structural understanding of Vif proteins. Curr HIV Res 2008, 6:91-99. 10.2174/157016208783885056, 2704546, 18336256.
20. Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, Yu XF. Differential Requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J Virol 2012, 87:1906-1911. 3554157, 23175372.
21. Hultquist JF, McDougle RM, Anderson BD, Harris RS. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor beta on genetically distinct surfaces. AIDS Res Hum Retroviruses 2012, 28:1543-1551. 10.1089/aid.2012.0142, 22725134.
22. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006, 80:3112-3115. 10.1128/JVI.80.6.3112-3115.2006, 1395459, 16501124.
23. Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 2007, 81:13235-13241. 10.1128/JVI.00204-07, 2169136, 17898068.
24. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007, 81:8201-8210. 10.1128/JVI.00395-07, 1951317, 17522216.
25. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J Virol 2011, 86:2874-2877. 3302251, 22205746.
26. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, Malim MH, Sanderson MR. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog 2010, 6:e1000925. 10.1371/journal.ppat.1000925, 2880568, 20532212.
27. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 2004, 18:2867-2872. 10.1101/gad.1250204, 534647, 15574593.
28. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, Yu XF, Xiong Y. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 2008, 82:8656-8663. 10.1128/JVI.00767-08, 2519636, 18562529.
29. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 2006, 281:17259-17265. 10.1074/jbc.M602413200, 16636053.
30. Paul I, Cui J, Maynard EL. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A 2006, 103:18475-18480. 10.1073/pnas.0604150103, 1693687, 17132731.
31. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006, 349:290-299. 10.1016/j.virol.2006.02.002, 16530799.
32. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A 2005, 102:11444-11449. 10.1073/pnas.0502440102, 1182177, 16076960.
33. Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2011, 481:376-379.
34. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD. CBFbeta Stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol Cell 2013, 49:632-644. 10.1016/j.molcel.2012.12.012, 23333304.
35. Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, et al. Global landscape of HIV-human protein complexes. Nature 2011, 481:365-370. 3310911, 22190034.
36. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, et al. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 2011, 481:371-375. 3310910, 22190037.
37. Bradsher JN, Jackson KW, Conaway RC, Conaway JW. RNA polymerase II transcription factor SIII. I: identification, purification, and properties. J Biol Chem 1993, 268:25587-25593.
38. Aso T, Lane WS, Conaway JW, Conaway RC. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995, 269:1439-1443. 10.1126/science.7660129, 7660129.
39. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 2001, 15:3104-3117. 10.1101/gad.926401, 312842, 11731475.
40. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2:423-427. 10.1038/35017054, 10878807.
41. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 2001, 21:3547-3557. 10.1128/MCB.21.10.3547-3557.2001, 100276, 11313480.
42. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A 1999, 96:2071-2076. 10.1073/pnas.96.5.2071, 26738, 10051596.
43. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009, 78:399-434. 10.1146/annurev.biochem.78.101807.093809, 19489725.
44. Kamura T, Sato S, Haque D, Liu L, Kaelin WG, Conaway RC, Conaway JW. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 1998, 12:3872-3881. 10.1101/gad.12.24.3872, 317264, 9869640.
45. Krek W. VHL takes HIF's breath away. Nat Cell Biol 2000, 2:E121-E123. 10.1038/35017129, 10878820.
46. Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, Hattori K, Hatakeyama S, Yada M, Morita S, et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem 2001, 276:12530-12538. 10.1074/jbc.M010074200, 11278610.
47. Brower CS, Shilatifard A, Mather T, Kamura T, Takagi Y, Haque D, Treharne A, Foundling SI, Conaway JW, Conaway RC. The elongin B ubiquitin homology domain: identification of Elongin B sequences important for interaction with Elongin C. J Biol Chem 1999, 274:13629-13636. 10.1074/jbc.274.19.13629, 10224134.
48. Garrett KP, Aso T, Bradsher JN, Foundling SI, Lane WS, Conaway RC, Conaway JW. Positive regulation of general transcription factor SIII by a tailed ubiquitin homolog. Proc Natl Acad Sci U S A 1995, 92:7172-7176. 10.1073/pnas.92.16.7172, 41301, 7638163.
49. Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S. Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure 2007, 15:1493-1504. 10.1016/j.str.2007.09.016, 2225448, 17997974.
50. Bullock AN, Debreczeni JE, Edwards AM, Sundstrom M, Knapp S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A 2006, 103:7637-7642. 10.1073/pnas.0601638103, 1472497, 16675548.
51. Zhou X, Evans SL, Han X, Liu Y, Yu XF. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFbeta and CRL5 E3 ubiquitin ligase components. PLoS One 2012, 7:e33495. 10.1371/journal.pone.0033495, 3316577, 22479405.
52. Reingewertz TH, Benyamini H, Lebendiker M, Shalev DE, Friedler A. The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. Protein Eng Des Sel 2009, 22:281-287. 10.1093/protein/gzp004, 19218568.
53. Hwang J, Saffert RT, Kalejta RF. Elongin B-mediated epigenetic alteration of viral chromatin correlates with efficient human cytomegalovirus gene expression and replication. MBio 2011, 2:e00023-00011. 3063379, 21447700.
54. Stopak K, De Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003, 12:591-601. 10.1016/S1097-2765(03)00353-8, 14527406.
55. Donahue JP, Vetter ML, Mukhtar NA, D'Aquila RT. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 2008, 377:49-53. 10.1016/j.virol.2008.04.017, 2474554, 18499212.
56. Akari H, Fujita M, Kao S, Khan MA, Shehu-Xhilaga M, Adachi A, Strebel K. High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J Biol Chem 2004, 279:12355-12362.
57. Izumi T, Takaori-Kondo A, Shirakawa K, Higashitsuji H, Itoh K, Io K, Matsui M, Iwai K, Kondoh H, Sato T, et al. MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology 2009, 6:1. 10.1186/1742-4690-6-1, 2629459, 19128510.
58. Schoenfeld AR, Davidowitz EJ, Burk RD. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci U S A 2000, 97:8507-8512. 10.1073/pnas.97.15.8507, 26978, 10900011.
59. Dang Y, Siew LM, Zheng YH. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J Biol Chem 2008, 283:13124-13131. 10.1074/jbc.M708728200, 2430655,2430655, 18326044.
60. Fujita M, Akari H, Sakurai A, Yoshida A, Chiba T, Tanaka K, Strebel K, Adachi A. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect 2004, 6:791-798. 10.1016/j.micinf.2004.04.011, 15374000.
61. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004, 279:7792-7798.
62. Fribourg S, Romier C, Werten S, Gangloff YG, Poterszman A, Moras D. Dissecting the interaction network of multiprotein complexes by pairwise coexpression of subunits in E. coli. J Mol Biol 2001, 306:363-373. 10.1006/jmbi.2000.4376, 11237605.
63. Tan S. A modular polycistronic expression system for overexpressing protein complexes in Escherichia coli. Protein Expr Purif 2001, 21:224-234. 10.1006/prep.2000.1363, 11162410.
64. Ellis RJ, Hartl FU. Principles of protein folding in the cellular environment. Curr Opin Struct Biol 1999, 9:102-110. 10.1016/S0959-440X(99)80013-X, 10047582.
65. Jaenicke R. Protein self-organization in vitro and in vivo: partitioning between physical biochemistry and cell biology. Biol Chem 1998, 379:237-243.
66. Bjornsson A, Mottagui-Tabar S, Isaksson LA. Structure of the C-terminal end of the nascent peptide influences translation termination. EMBO J 1996, 15:1696-1704. 450081, 8612594.
67. Banci L, Bertini I, Cusack S, De Jong RN, Heinemann U, Jones EY, Kozielski F, Maskos K, Messerschmidt A, Owens R, et al. First steps towards effective methods in exploiting high-throughput technologies for the determination of human protein structures of high biomedical value. Acta Crystallogr D: Biol Crystallogr 2006, 62:1208-1217.
68. Peti W, Page R. Strategies to maximize heterologous protein expression in Escherichia coli with minimal cost. Protein Expr Purif 2007, 51:1-10. 10.1016/j.pep.2006.06.024, 16904906.
69. Fogg MJ, Alzari P, Bahar M, Bertini I, Betton JM, Burmeister WP, Cambillau C, Canard B, Corrondo MA, Coll M, et al. Application of the use of high-throughput technologies to the determination of protein structures of bacterial and viral pathogens. Acta Crystallogr D: Biol Crystallogr 2006, 62:1196-1207.
70. Ohh M, Takagi Y, Aso T, Stebbins CE, Pavletich NP, Zbar B, Conaway RC, Conaway JW, Kaelin WG. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest 1999, 104:1583-1591. 10.1172/JCI8161, 481054, 10587522.
71. Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999, 284:455-461. 10.1126/science.284.5413.455, 10205047.
72. Vijay-Kumar S, Bugg CE, Cook WJ. Structure of ubiquitin refined at 1.8 A resolution. J Mol Biol 1987, 194:531-544. 10.1016/0022-2836(87)90679-6, 3041007.
73. Luo K, Ehrlich E, Xiao Z, Zhang W, Ketner G, Yu XF. Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. FASEB J 2007, 21:1742-1750. 10.1096/fj.06-7241com, 17351129.
74. Kinoshita K, Goryo K, Takada M, Tomokuni Y, Aso T, Okuda H, Shuin T, Fukumura H, Sogawa K. Ternary complex formation of pVHL, elongin B and elongin C visualized in living cells by a fluorescence resonance energy transfer-fluorescence lifetime imaging microscopy technique. FEBS J 2007, 274:5567-5575. 10.1111/j.1742-4658.2007.06075.x, 17922844.
75. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996, 381:571-579. 10.1038/381571a0, 8637592.
76. Martinez-Vicente M, Sovak G, Cuervo AM. Protein degradation and aging. Exp Gerontol 2005, 40:622-633. 10.1016/j.exger.2005.07.005, 16125351.
77. Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One 2008, 3:e3963. 10.1371/journal.pone.0003963, 2597746, 19088851.
78. Zuo T, Liu D, Lv W, Wang X, Wang J, Lv M, Huang W, Wu J, Zhang H, Jin H, et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J Virol 2012, 86:5497-5507. 10.1128/JVI.06957-11, 3347289, 22379088.